Post-Exposure Prophylaxis (PEP) of Respiratory Syncytial Virus (RSV) Infection After High-Inoculum RSV Human Challenge: Analysis of a Randomized Double-Blind, Placebo-Controlled Trial of EDP-323, an Oral, Non-Nucleoside Polymerase Inhibitor Antiviral

EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower RespiratoryTract RSV Symptoms and Viral Load After Human Viral Challenge

EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study

EDP-323, a First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV: Results from a Phase 2a Human Viral Challenge Study

EDP-323 Challenge Study Topline Data Results

EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity

Pharmacokinetics of EDP-323, a Potent, Once-Daily, Oral Antiviral Treatment for Respiratory Syncytial Virus

EDP-323, a Small Molecule L-Protein Inhibitor, in Development Against Respiratory Syncytial Virus

EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus

In Vivo Efficacy of EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus